These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 9691224)

  • 21. Initial cleavage of the human immunodeficiency virus type 1 GagPol precursor by its activated protease occurs by an intramolecular mechanism.
    Pettit SC; Everitt LE; Choudhury S; Dunn BM; Kaplan AH
    J Virol; 2004 Aug; 78(16):8477-85. PubMed ID: 15280456
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The human immunodeficiency virus type 1 carboxyl-terminal third of capsid sequence in Gag-Pol is essential but not sufficient for efficient incorporation of Pr160(gag-pol) into virus particles.
    Chiu HC; Liao WH; Chen SW; Wang CT
    J Biomed Sci; 2004; 11(3):398-407. PubMed ID: 15067224
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Expression and immunogenicity of sequence-modified human immunodeficiency virus type 1 subtype B pol and gagpol DNA vaccines.
    zur Megede J; Otten GR; Doe B; Liu H; Leung L; Ulmer JB; Donnelly JJ; Barnett SW
    J Virol; 2003 Jun; 77(11):6197-207. PubMed ID: 12743276
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Human immunodeficiency virus type 1 (HIV-1) protein Vif inhibits the activity of HIV-1 protease in bacteria and in vitro.
    Kotler M; Simm M; Zhao YS; Sova P; Chao W; Ohnona SF; Roller R; Krachmarov C; Potash MJ; Volsky DJ
    J Virol; 1997 Aug; 71(8):5774-81. PubMed ID: 9223465
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Maintenance of the Gag/Gag-Pol ratio is important for human immunodeficiency virus type 1 RNA dimerization and viral infectivity.
    Shehu-Xhilaga M; Crowe SM; Mak J
    J Virol; 2001 Feb; 75(4):1834-41. PubMed ID: 11160682
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Polymorphisms in p1-p6/p6* of HIV type 1 can delay protease autoprocessing and increase drug susceptibility.
    Whitehurst N; Chappey C; Petropoulos C; Parkin N; Gamarnik A
    AIDS Res Hum Retroviruses; 2003 Sep; 19(9):779-84. PubMed ID: 14585208
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cooperative contribution of gag substitutions to nelfinavir-dependent enhancement of precursor cleavage and replication of human immunodeficiency virus type-1.
    Matsuoka-Aizawa S; Gatanaga H; Sato H; Koike K; Kimura S; Oka S
    Antiviral Res; 2006 Jun; 70(2):51-9. PubMed ID: 16487604
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficient particle production by minimal Gag constructs which retain the carboxy-terminal domain of human immunodeficiency virus type 1 capsid-p2 and a late assembly domain.
    Accola MA; Strack B; Göttlinger HG
    J Virol; 2000 Jun; 74(12):5395-402. PubMed ID: 10823843
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Functional RT and IN incorporated into HIV-1 particles independently of the Gag/Pol precursor protein.
    Wu X; Liu H; Xiao H; Conway JA; Hunter E; Kappes JC
    EMBO J; 1997 Aug; 16(16):5113-22. PubMed ID: 9305652
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Human immunodeficiency virus (HIV) type 1 transframe protein can restore activity to a dimerization-deficient HIV protease variant.
    Dautin N; Karimova G; Ladant D
    J Virol; 2003 Aug; 77(15):8216-26. PubMed ID: 12857890
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Polymorphism of HIV type 1 gag p7/p1 and p1/p6 cleavage sites: clinical significance and implications for resistance to protease inhibitors.
    Bally F; Martinez R; Peters S; Sudre P; Telenti A
    AIDS Res Hum Retroviruses; 2000 Sep; 16(13):1209-13. PubMed ID: 10957718
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Morphogenic capabilities of human immunodeficiency virus type 1 gag and gag-pol proteins in insect cells.
    Hughes BP; Booth TF; Belyaev AS; McIlroy D; Jowett J; Roy P
    Virology; 1993 Mar; 193(1):242-55. PubMed ID: 8438569
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A Functional Interplay between Human Immunodeficiency Virus Type 1 Protease Residues 77 and 93 Involved in Differential Regulation of Precursor Autoprocessing and Mature Protease Activity.
    Counts CJ; Ho PS; Donlin MJ; Tavis JE; Chen C
    PLoS One; 2015; 10(4):e0123561. PubMed ID: 25893662
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Gag-Pol Transframe Domain p6* Is Essential for HIV-1 Protease-Mediated Virus Maturation.
    Yu FH; Chou TA; Liao WH; Huang KJ; Wang CT
    PLoS One; 2015; 10(6):e0127974. PubMed ID: 26030443
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Extensive regions of pol are required for efficient human immunodeficiency virus polyprotein processing and particle maturation.
    Quillent C; Borman AM; Paulous S; Dauguet C; Clavel F
    Virology; 1996 May; 219(1):29-36. PubMed ID: 8623542
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Analysis of human immunodeficiency virus type 1 containing HERV-K protease.
    Padow M; Lai L; Fisher RJ; Zhou YC; Wu X; Kappes JC; Towler EM
    AIDS Res Hum Retroviruses; 2000 Dec; 16(18):1973-80. PubMed ID: 11153080
    [TBL] [Abstract][Full Text] [Related]  

  • 37. HIV-1 protease dimer interface mutations that compensate for viral reverse transcriptase instability in infectious virions.
    Olivares I; Mulky A; Boross PI; Tözsér J; Kappes JC; López-Galíndez C; Menéndez-Arias L
    J Mol Biol; 2007 Sep; 372(2):369-81. PubMed ID: 17651754
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Functional characterization of the protease of human endogenous retrovirus, K10: can it complement HIV-1 protease?
    Towler EM; Gulnik SV; Bhat TN; Xie D; Gustschina E; Sumpter TR; Robertson N; Jones C; Sauter M; Mueller-Lantzsch N; Debouck C; Erickson JW
    Biochemistry; 1998 Dec; 37(49):17137-44. PubMed ID: 9860826
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Analysis of protein expression and virus-like particle formation in mammalian cell lines stably expressing HIV-1 gag and env gene products with or without active HIV proteinase.
    Kräusslich HG; Ochsenbauer C; Traenckner AM; Mergener K; Fäcke M; Gelderblom HR; Bosch V
    Virology; 1993 Feb; 192(2):605-17. PubMed ID: 8421902
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Blocking of human immunodeficiency virus type-1 virion autolysis by autologous p2(gag) peptide.
    Misumi S; Morikawa Y; Tomonaga M; Ohkuma K; Takamune N; Shoji S
    J Biochem; 2004 Mar; 135(3):447-53. PubMed ID: 15113844
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.